KN035 in Patients With Advanced Multiple Primary Tumors
Status:
Unknown status
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
This study is a prospective, single arm, single center exploratory clinical research, to
evaluate KN035 late treatment in patients with Multiple Primary tumors (MPC, Multiple Primary
working) clinical benefit.In the study, all subjects meeting the criteria for inclusion will
be enrolled in the KN035 treatment group, and patients cannot receive any other anti-tumor
treatment during the study period.The primary endpoint of the study was defined as patients
who could be assessed by imaging, and the optimal Objective Response Rate (ORR) based on
RECIST 1.1 standard, while the secondary endpoint was safety (nci-ctcae 4.0), DCR (Disease
Control Rate), DoR (Duration of Response), progression-free survival (PFS),1) Overall
Survival and Overall Survival;The end point of the exploratory study was the correlation
between different molecular types and the efficacy of immunotherapy.